These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 31642931)

  • 1. Assessment of Diagnostic Outcomes of RNA Genetic Testing for Hereditary Cancer.
    Karam R; Conner B; LaDuca H; McGoldrick K; Krempely K; Richardson ME; Zimmermann H; Gutierrez S; Reineke P; Hoang L; Allen K; Yussuf A; Farber-Katz S; Rana HQ; Culver S; Lee J; Nashed S; Toppmeyer D; Collins D; Haynes G; Pesaran T; Dolinsky JS; Tippin Davis B; Elliott A; Chao E
    JAMA Netw Open; 2019 Oct; 2(10):e1913900. PubMed ID: 31642931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic Outcomes of Concurrent DNA and RNA Sequencing in Individuals Undergoing Hereditary Cancer Testing.
    Horton C; Hoang L; Zimmermann H; Young C; Grzybowski J; Durda K; Vuong H; Burks D; Cass A; LaDuca H; Richardson ME; Harrison S; Chao EC; Karam R
    JAMA Oncol; 2024 Feb; 10(2):212-219. PubMed ID: 37924330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing.
    Mersch J; Brown N; Pirzadeh-Miller S; Mundt E; Cox HC; Brown K; Aston M; Esterling L; Manley S; Ross T
    JAMA; 2018 Sep; 320(12):1266-1274. PubMed ID: 30264118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
    Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
    JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Variant Reclassification in Cancer Predisposition Genes on Clinical Care.
    Chiang J; Chia TH; Yuen J; Shaw T; Li ST; Binte Ishak ND; Chew EL; Chong ST; Chan SH; Ngeow J
    JCO Precis Oncol; 2021 Nov; 5():577-584. PubMed ID: 34994607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rates and Classification of Variants of Uncertain Significance in Hereditary Disease Genetic Testing.
    Chen E; Facio FM; Aradhya KW; Rojahn S; Hatchell KE; Aguilar S; Ouyang K; Saitta S; Hanson-Kwan AK; Capurro NN; Takamine E; Jamuar SS; McKnight D; Johnson B; Aradhya S
    JAMA Netw Open; 2023 Oct; 6(10):e2339571. PubMed ID: 37878314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variant classification changes over time in the clinical molecular diagnostic laboratory setting.
    Hahn E; Mighton C; Fisher Y; Wong A; Di Gioacchino V; Watkins N; Mayers J; Bombard Y; Charames GS; Lerner-Ellis J
    J Med Genet; 2024 Jul; 61(8):788-793. PubMed ID: 38806232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Observed frequency and challenges of variant reclassification in a hereditary cancer clinic.
    Macklin S; Durand N; Atwal P; Hines S
    Genet Med; 2018 Mar; 20(3):346-350. PubMed ID: 29215655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing.
    Chang J; Seng S; Yoo J; Equivel P; Lum SS
    Ann Surg Oncol; 2019 Oct; 26(10):3389-3396. PubMed ID: 31342386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer.
    Whitworth PW; Beitsch PD; Patel R; Rosen B; Compagnoni G; Baron PL; Simmons R; Brown EA; Gold L; Holmes D; Smith LA; Kinney M; Grady I; Clark P; Barbosa K; Lyons S; Riley L; Coomer C; Curcio L; Ruiz A; Khan S; MacDonald H; Hughes K; Hardwick MK; Heald B; Munro SB; Nielsen SM; Esplin ED
    JAMA Netw Open; 2022 Sep; 5(9):e2232787. PubMed ID: 36136330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter study of clinical impact of variant of uncertain significance reclassification in breast, ovarian and colorectal cancer susceptibility genes.
    Makhnoon S; Levin B; Ensinger M; Mattie K; Volk RJ; Zhao Z; Mendoza T; Shete S; Samiian L; Grana G; Grainger A; Arun B; Shirts BH; Peterson SK
    Cancer Med; 2023 Feb; 12(3):2875-2884. PubMed ID: 36426404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-gene panel testing for hereditary cancer susceptibility in a rural Familial Cancer Program.
    Hermel DJ; McKinnon WC; Wood ME; Greenblatt MS
    Fam Cancer; 2017 Jan; 16(1):159-166. PubMed ID: 27401692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome.
    Yurgelun MB; Allen B; Kaldate RR; Bowles KR; Judkins T; Kaushik P; Roa BB; Wenstrup RJ; Hartman AR; Syngal S
    Gastroenterology; 2015 Sep; 149(3):604-13.e20. PubMed ID: 25980754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of variant reclassification and patient re-contact in a cancer genetics clinic.
    Muir SM; Reagle R
    J Genet Couns; 2022 Dec; 31(6):1261-1272. PubMed ID: 35763673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients.
    Lincoln SE; Kobayashi Y; Anderson MJ; Yang S; Desmond AJ; Mills MA; Nilsen GB; Jacobs KB; Monzon FA; Kurian AW; Ford JM; Ellisen LW
    J Mol Diagn; 2015 Sep; 17(5):533-44. PubMed ID: 26207792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Utility of Functional RNA Analysis for the Reclassification of Splicing Gene Variants in Hereditary Cancer.
    Agiannitopoulos K; Pepe G; Papadopoulou E; Tsaousis GN; Kampouri S; Maravelaki S; Fassas A; Christodoulou C; Iosifidou R; Karageorgopoulou S; Markopoulos C; Natsiopoulos I; Papazisis K; Vasilaki-Antonatou M; Venizelos V; Ozmen V; Tansan S; Kaban K; Eniu DT; Chiorean A; Nasioulas G
    Cancer Genomics Proteomics; 2021; 18(3):285-294. PubMed ID: 33893081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Utility of Reinterpreting Previously Reported Genomic Epilepsy Test Results for Pediatric Patients.
    SoRelle JA; Thodeson DM; Arnold S; Gotway G; Park JY
    JAMA Pediatr; 2019 Jan; 173(1):e182302. PubMed ID: 30398534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings.
    Seifert BA; O'Daniel JM; Amin K; Marchuk DS; Patel NM; Parker JS; Hoyle AP; Mose LE; Marron A; Hayward MC; Bizon C; Wilhelmsen KC; Evans JP; Earp HS; Sharpless NE; Hayes DN; Berg JS
    Clin Cancer Res; 2016 Aug; 22(16):4087-4094. PubMed ID: 27083775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spectrum of splicing variants in disease genes and the ability of RNA analysis to reduce uncertainty in clinical interpretation.
    Truty R; Ouyang K; Rojahn S; Garcia S; Colavin A; Hamlington B; Freivogel M; Nussbaum RL; Nykamp K; Aradhya S
    Am J Hum Genet; 2021 Apr; 108(4):696-708. PubMed ID: 33743207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of variant classification on the clinical management of hereditary cancer syndromes.
    Turner SA; Rao SK; Morgan RH; Vnencak-Jones CL; Wiesner GL
    Genet Med; 2019 Feb; 21(2):426-430. PubMed ID: 29875428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.